Tag: #Global Trends

Deal Context: Expanding the Therapeutic Toolbox Following its promising ventures into the obesity market, New York-based Regeneron Pharmaceuticals has officially... Read more

Event Context: Eli Lilly’s Fourth Strategic Victory On April 13, 2026, Eli Lilly announced positive results from the Phase 3... Read more

The Incident: Allegations of Misleading Social Media Promotions The U.S. Food and Drug Administration (FDA) has issued an untitled letter... Read more

The pharmaceutical industry has entered a new chapter in the obesity treatment race as Eli Lilly officially launched Foundayo (orforglipron),... Read more

Pharmaceutical giant AbbVie has launched a legal challenge against the U.S. Department of Health and Human Services (HHS) and the... Read more

GC Biopharma has successfully developed and validated a proprietary assay designed to precisely measure impurities linked to thromboembolic risks. This... Read more

Halozyme Therapeutics Inc. has finalized a global exclusive collaboration and licensing agreement with Vertex Pharmaceuticals Incorporated. Under this pact, Vertex... Read more

AC Immune SA and Eli Lilly and Company have officially amended their 2018 licensing and collaboration agreement to advance the... Read more

Pharmaceutical giant Biocon has officially commenced the commercial launch of two biosimilars, Aukelso and Bosaya, in the United States. These... Read more